Message #28 From:
Stock News Bot Date: October 31, 2006 05:00:00 AM
CLRI News Clearant to Present at the Rodman and Renshaw 8th Annual Healthcare Conference
LOS ANGELES--(BUSINESS WIRE)--Clearant, Inc. (OTCBB:CLRI) today announced that the Company will
present at the Rodman & Renshaw 8th Annual
Healthcare Conference to be held at the Palace Hotel in New York on
November 6-8, 2006.
Alain Delongchamp, chief executive officer of Clearant, will present on
Tuesday, November 7, 2006 at 10:35 a.m. Eastern time (7:35 a.m. Pacific
time), and will provide an update on the Company’s
new direct sales growth initiative, which started in June 2006 and is
designed to sell its Clearant Process sterile implants directly to
hospitals and end user surgeons.
Interested parties can access a live audio webcast [and
slide presentation] via the Internet by
visiting the Investor Relations section of Clearant’s
Web site at www.clearant.com. An
archived presentation will be available on the Web site for 14 days.
About Clearant, Inc.
Clearant, Inc. is a leader in pathogen inactivation for biological
products. Clearant has developed the patent-protected Clearant Process,
which substantially reduces all types of bacteria and viruses in
biological products while maintaining the functionality of the
underlying tissue implant or protein. The Company began to distribute
directly to surgeons, hospitals and clinics Clearant Process sterile
implants in June 2006; in addition, Clearant continues to license the
Clearant Process and provides its patented sterilization services to
tissue banks and other biological products manufacturers. Clearant also
has 10 license and service agreements with tissue banks. To date more
than 8,000 patients have been successfully implanted with Clearant
Process sterile implants supplied by one of the Company's licensed
partners. Whereas various competing sterilization methods only kill
specific types of pathogens (such as bacteria or lipid-enveloped
viruses) for specific products, the Clearant Process reduces all types
of pathogens for products across many market segments including tissue
implants, plasma proteins, recombinant products, medical devices and
blood products. Also, the Clearant Process can be applied at various
stages of product processing and/or manufacturing, including in the
final packaging. For more information, please visit www.clearant.com.
